



Please indicate any Pulmonary Vascular Disease topics you will be seeking information on in the next 12 months.

- New PH therapies and treatment. (**24 responses**)
- New medications. (**7 responses**)
- New therapies. (**7 responses**)
- Pulmonary Hypertension. (**7 responses**)
- Lung transplant in Pulmonary Hypertension. (**6 responses**)
- CTEPH. (**5 responses**)
- Right ventricular failure and pulmonary hypertension. (**4 responses**)
- Clinical trials. (**3 responses**)
- Emerging treatments. (**3 responses**)
- PH-ILD. (**3 responses**)
- Pulmonary Arterial Hypertension (**3 responses**)
- Pulmonary hypertension treatment updates. (**3 responses**)
- Use of pulmonary vasodilators in RVF...does it actually work? (**3 responses**)
- Group 2 PH if anything is in the works. (**2 responses**)
- Group 3 PH with its emerging new therapies. (**2 responses**)
- More content. (**2 responses**)
- Transplantation in PH. (**2 responses**)
- Additional insights into pathophysiology and targeted PAH therapies
- Adult congenital heart.
- Advanced therapies for children.
- advances in management of pHTN
- AHP.
- Any improvements in care for high risk individuals.
- ATS.
- CLAD/BOS assessment
- Controversial topics.
- COVID related.
- CPCPH management.
- CTEPH and PAH diagnosis in setting of advanced heart failure.
- CTEPH best practices.
- CTEPH surgery population differences - *ct surgery*
- CTEPH team management.
- Current LAS/exemptions for PH.
- Definitely would like to see more data presented on the use of PAH disease specific medications or new therapies for PH in ILD patients.
- Evaluation of PAH.
- Expanding surgical and catheter based interventions.
- Group 5 PH - How do we manage?



Please indicate any Pulmonary Vascular Disease topics you will be seeking information on in the next 12 months. -- *continued*

- Heart failure in PVD. New Treatments of advanced PVD. Timing and balancing surgical interventions in PVD MCS in PH.
- Heart/lung transplantation in PH patients.
- Highlighting APP practice.
- How simpler interventions like dietary changes/avoidance of TMAO generating meals can affect management of PAH.
- Hypertension.
- Improvement in HF population and thromboembolic disease.
- Innovative treatment of acute pulmonary embolism.
- International guidelines on PH will be presented in 8/2022 (and endorsed by the ISHLT). This would definitely deserve at least one session: A) describing the major advances since 2015 B) addressing the gaps in evidence for the ISHLT members.
- IPAH.
- Linking COVID to PVD.
- Liver transplant and lung transplant in PH.
- Management of CTEPH, role of advanced imaging in prognostication and management. *This would apply to physicians/NPs in Cardiology, Pulmonology, and CT surgery.*
- Management of pulmonary vascular disease patients for non-cardiac surgery - *Anaesth/Critical Care / Surgery / Cardiology*
- Mayo Clinic Thoracic Pathology Workshop. *(Pathology, obviously)*
- Methamphetamine Associated PAH.
- MORE DATA ON THE OCS
- More on tailoring PH therapies/multiple therapies.
- More PH discussions for general management: acute and chronic.
- Multimodal management of CTEPH
- new advancements to therapy. novel treatment pathways
- New therapeutic targets, ongoing trials, actively growing our CTEPH program, looking for data/experience with BPA
- Newest RCT on PAH
- Noninvasive diagnosis.
- Palliation courses.
- Pathophysiology Treatment protocols. Parenteral use and weaning.
- PEA perioperative management.
- Pediatric PAH specific oral therapy regimens.
- Pediatric PVD topics.
- perioperative anesthetic management of patients with PHTN
- Physiologic mechanisms to describe/explain this heterogenous group of patients.
- Post-op lung Tx management.
- Potential updates in guidelines.
- Pulmonary Angioplasty



Please indicate any Pulmonary Vascular Disease topics you will be seeking information on in the next 12 months. -- *continued*

- Pulmonary embolism devices, surgery for CPTEH.
- PVD pre-txp.
- PVOD vs PAH.
- PVR.
- Results.
- Reverse remodeling- PHA.
- RV decoupling and pulmonary hypertension in LVAD patients.
- Secondary PHT in congenital heart disease and DCM.
- Session on implantable / remote monitoring.
- So helpful about multiorgan transplant data regarding when it is appropriate to do single vs. multiorgan transplants. I wonder if this would be more.
- The PTE procedure and setting up a CTEPH program.
- Thromboendarterectomy.
- Topics to engage Cardiologists.
- Treatments for pediatric patients with PVR issues secondary to LV failure.
- use of pulmonary vasodilators in group 2 HNT post VAD.
- VAD and PAH.
- What is next for CTEPH - surgical perspectives.
- Where we are on pathologic diagnosis of PVD and how lung biopsy features correlate with clinical parameters and outcomes as well as contribute to management decisions. This topic is relevant to many professional communities.
- Would like to see studies that assess effect of the microbioma and its effect on management of different PH groups and severities